Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 10;10(1):392.
doi: 10.1186/s13104-017-2731-5.

The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka

Nirmala Dushyanthi Sirisena  1 , Kemal Deen  2 , Dayupathi Eranda Nipunika Mandawala  3 , Pumindu Herath  3 , Vajira Harshadeva Weerabaddana Dissanayake  4   3
Affiliations

The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka

Nirmala Dushyanthi Sirisena et al. BMC Res Notes. .

Abstract

Objective: Activating mutations in the KRAS gene, found in approximately 53% of metastatic colorectal cancer (mCRC) cases, can render epidermal growth factor receptor (EGFR) inhibitors ineffective. Regional differences in these mutations have been reported. This is the first study which aims to describe the pattern of KRAS mutations in a Sri Lankan cohort of mCRC patients.

Results: The KRAS genotypes detected in mCRC patients which have been maintained in an anonymized database were retrospectively analyzed. Of the 108 colorectal tissue samples tested, 25 (23.0%) had KRAS mutations. Overall, there were 68 (63.0%) males and 40 (37.0%) females. Among the KRAS positive cases, there were 14 (56.0%) males and 11 (44.0%) females. Their age distribution ranged from 29 to 85 years with a median age of 61 years. There were 15 patients (60.0%) with point mutations in codon 12 while 10 (40.0%) had a single mutation in codon 13. The most common KRAS mutation identified was p.Gly13Asp (40.0%), followed by p.Gly12Val (24.0%). Other mutations included p.Gly12Cys (12.0%), p.Gly12Ser (12.0%), p.Gly12Asp (8.0%), and p.Gly12Arg (4.0%). The codon 13 mutation was a G>A transition (40.0%), while G>T transversions (32.0%), G>A transitions (24.0%), and G>C transversions (4.0%) were found in the codon 12 mutations. The frequency of KRAS mutations was similar to that reported for Asian patients. However, in contrast to several published studies, the G>A transition in codon 12 (c.35G>A; p.Gly12Asp), was not the most common mutation within codon 12 in our cohort. This may be a reflection of the genetic heterogeneity in the pattern of KRAS mutations in mCRC patients but valid conclusions cannot be drawn from these preliminary findings due to the small size of the study sample.

Keywords: Colorectal carcinoma; Epidermal growth factor receptor; Genotype; KRAS gene; Mutation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage distribution of the mutant KRAS (G>A) transitions and (G>T) and (G>C) transversions in the study cohort
Fig. 2
Fig. 2
Percentage distribution of the KRAS mutations according to gender
Fig. 3
Fig. 3
Percentage distribution of the mutant KRAS mutations according to age groups
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer Registry, National Cancer Control Programme. Sri Lanka cancer incidence data 2007; 2013.
    1. Inoue Y, Saigusa S, Iwata T, Okugawa Y, Toiyama Y, Tanaka K, et al. The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Rep. 2012;28:1579–1584. - PubMed
    1. Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol. 2012;18:5171–5180. doi: 10.3748/wjg.v18.i42.6127. - DOI - PMC - PubMed
    1. Harlé A, Filhine-Tresarrieu P, Husson M, Boidot R, Rouyer M, Dubois C, et al. Rare RAS mutations in metastatic colorectal cancer detected during routine RAS genotyping using next generation sequencing. Target Oncol. 2016;11:363–370. doi: 10.1007/s11523-015-0404-7. - DOI - PubMed
    1. Yamane L, Scapulatempo-Neto C, Reis RM, Guimaraes D. Serrated pathway in colorectal carcinogenesis. World J Gastroenterol. 2014;20:2634–2640. doi: 10.3748/wjg.v20.i10.2634. - DOI - PMC - PubMed

Substances